174 related articles for article (PubMed ID: 32353010)
1. Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
Faure Bardon V; Peytavin G; Lê MP; Guilleminot T; Elefant E; Stirnemann J; Leruez-Ville M; Ville Y
PLoS One; 2020; 15(4):e0232140. PubMed ID: 32353010
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
3. Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.
Vinot C; Gavard L; Tréluyer JM; Manceau S; Courbon E; Scherrmann JM; Declèves X; Duro D; Peytavin G; Mandelbrot L; Giraud C
Antimicrob Agents Chemother; 2013 Mar; 57(3):1415-20. PubMed ID: 23295922
[TBL] [Abstract][Full Text] [Related]
4. Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.
Hamilton ST; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077661
[TBL] [Abstract][Full Text] [Related]
5. Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model.
Faure-Bardon V; Mandelbrot L; Duro D; Dussaux C; Le M; Peytavin G
AIDS; 2018 Jan; 32(3):321-325. PubMed ID: 29112064
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model.
Russo FM; Conings S; Allegaert K; Van Mieghem T; Toelen J; Van Calsteren K; Annaert P; Deprest J
Am J Obstet Gynecol; 2018 Dec; 219(6):619.e1-619.e10. PubMed ID: 30194048
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the maternal-fetal transfer of granisetron in an ex vivo placenta perfusion model.
Julius JM; Tindall A; Moise KJ; Refuerzo JS; Berens PD; Smith JA
Reprod Toxicol; 2014 Nov; 49():43-7. PubMed ID: 25019977
[TBL] [Abstract][Full Text] [Related]
8. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Oiknine-Djian E; Bar-On S; Laskov I; Lantsberg D; Haynes RK; Panet A; Wolf DG
Antiviral Res; 2019 Dec; 172():104639. PubMed ID: 31654672
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo model of congenital cytomegalovirus infection and new combination therapies.
Morère L; Andouard D; Labrousse F; Saade F; Calliste CA; Cotin S; Aubard Y; Rawlinson WD; Esclaire F; Hantz S; Ploy MC; Alain S
Placenta; 2015 Jan; 36(1):41-7. PubMed ID: 25479789
[TBL] [Abstract][Full Text] [Related]
10. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Jovelet C; Seck A; Mir O; Simasotchi C; Broutin S; Goffinet F; Bidart JM; Paci A; Gil S
Ann Oncol; 2015 Jul; 26(7):1500-4. PubMed ID: 25851627
[TBL] [Abstract][Full Text] [Related]
11. Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Alain S; Revest M; Veyer D; Essig M; Rerolles JP; Rawlinson W; Mengelle C; Huynh A; Kamar N; Garrigue I; Kaminski H; Segard C; Presne C; Mazeron MC; Avettant-Fenoël V; Lecuit M; Lortholary O; Coaquette A; Hantz S; Leruez-Ville M; Ploy MC
Transplant Proc; 2013 May; 45(4):1603-7. PubMed ID: 23726629
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
13. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
14. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
15. Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model.
Schalkwijk S; Greupink R; Colbers AP; Wouterse AC; Verweij VG; van Drongelen J; Teulen M; van den Oetelaar D; Burger DM; Russel FG
J Antimicrob Chemother; 2016 Feb; 71(2):480-3. PubMed ID: 26538508
[TBL] [Abstract][Full Text] [Related]
16. Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.
Gavard L; Beghin D; Forestier F; Cayre Y; Peytavin G; Mandelbrot L; Farinotti R; Gil S
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):157-60. PubMed ID: 19773109
[TBL] [Abstract][Full Text] [Related]
17. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
[TBL] [Abstract][Full Text] [Related]
18. Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model.
Pencolé L; Lê MP; Bouchet-Crivat F; Duro D; Peytavin G; Mandelbrot L
AIDS; 2020 Nov; 34(14):2145-2149. PubMed ID: 32796211
[TBL] [Abstract][Full Text] [Related]
19. Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model.
Mandelbrot L; Duro D; Belissa E; Peytavin G
Antimicrob Agents Chemother; 2015 May; 59(5):2901-3. PubMed ID: 25691637
[TBL] [Abstract][Full Text] [Related]
20. Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.
Mandelbrot L; Ceccaldi PF; Duro D; Lê M; Pencolé L; Peytavin G
PLoS One; 2019; 14(8):e0220323. PubMed ID: 31408460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
